Quick Takeaways
- Paradigm Biocapital Advisors LP filed SCHEDULE 13G/A for Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share (EWTX).
- Disclosed ownership: 6.2%.
- Date of event: 31 Dec 2025.
Paradigm Biocapital Advisors LP - 31 Dec 2025 SCHEDULE 13G/A Report for Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share (EWTX)
- Filing Manager
- Paradigm Biocapital Advisors LP
- Reporting Manager
- Paradigm BioCapital Advisors LP
- Symbol
- EWTX
- Shares outstanding
- 105,503,387 shares
- Disclosed Ownership
- 6,541,210 shares
- Ownership
- 6.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:02:54 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 03 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Paradigm Biocapital Advisors LP disclosed 6.2% ownership in Edgewise Therapeutics, Inc. Common Stock, $0.0001 par value per share (EWTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 03 Feb 2025.
- Current filing was accepted on 17 Feb 2026, 16:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 6.2% | 6,541,210 | 6,541,210 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Paradigm BioCapital Advisors GP LLC | 6.2% | 6,541,210 | 6,541,210 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory | |
| Senai Asefaw, M.D. | 6.2% | 6,541,210 | 6,541,210 | 0 | /s/ Senai Asefaw, M.D. | N/A | |
| Paradigm BioCapital International Fund Ltd. | 5.5% | 5,778,924 | 5,778,924 | 0 | /s/ David K. Kim | David K. Kim / Authorized Signatory |